Developing innovative ocular solutions
Nicox is an international ophthalmology company developing innovative therapeutics to help maintain vision and improve ocular health. We aim to be a fully integrated ophthalmic pharmaceutical with a direct presence in the U.S and in the major European markets.
We will achieve our goal by advancing our product candidates through clinical development to approval in the U.S. and EU markets, optimizing their development and commercialization in the rest of the world through partnerships, and expanding our pipeline with new internal research and development projects, potential in-licensing or acquisitions of ophthalmic development candidates or approved products.
Our ophthalmic pipeline includes two programs in clinical development, NCX 470 targeting glaucoma and NCX 4251 targeting blepharitis. We also have two products which are commercialized in the U.S., VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% and ZERVIATE® (cetirizine ophthalmic solution) 0.24%, for use in patients with open-angle glaucoma and ocular allergic conjunctivitis, respectively, and which are being rolled-out in territories outside of the U.S. through partnerships.